SequelSEC

Axsome Therapeutics, Inc. AXSM

Pharmaceutical Preparations · CIK 0001579428 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$776.57M
Fiscal year ended 2026-06-30
Operating income
-$186.07M
Fiscal year ended 2026-06-30
Free cash flow
-$71.96M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$4.40BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$86.02Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue6.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity49.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.1%10th
Long-term debt / equity1.33x86th
Revenue YoY growth65.5%79th
Current ratio1.55x22th
R&D / revenue28.7%28th
Operating margin-26.1%69th
Net margin-28.7%65th
FCF margin-14.7%63th
SBC / revenue14.7%42th

Axsome Therapeutics, Inc. (AXSM) reported revenue of $776.57M and net income of -$191.64M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Axsome Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Axsome Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$776.57M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$186.07M
Net income-$191.64M
Research & development$187.86M
Weighted-average diluted sharesUnavailable
Pretax income-$191.09M
Income tax expense$558.00K
Diluted EPSUnavailable
Selling, general & administrative$712.66M
General & administrative$85.03M
Selling & marketing$559.29M

Balance

Axsome Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$319.85M
Total assets$761.45M
Current assets$656.57M
Total liabilities$678.14M
Current liabilities$460.45M
Total equity incl. NCI$83.30M
Temporary (mezzanine) equityUnavailable
Inventory$37.88M
Accounts receivable$277.46M
Goodwill$12.04M
Long-term debt$117.96M
Accounts payable$78.97M

Cash flow

Axsome Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$71.26M
Capital expenditures$700.00K
Investing cash flow-$700.00K
Financing cash flow$88.79M
Net change in cash$16.83M
Stock-based compensation$96.42M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Axsome Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$71.96M
Gross marginUnavailable
Operating margin-24.0%
FCF margin-9.3%
SBC / revenue12.4%
Current ratio1.43x
Revenue YoY growth56.9%
Net margin-24.7%
R&D / revenue24.2%
CapEx / revenue0.1%
Long-term debt / equity1.42x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AXSM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-23View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.